How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

690 results for

Dysuria in Children

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Urological Infections

measures 29 3E.5.2 Treatment 30 3E.5.2.1 Relief of obstruction 30 3E.5.2.2 Antimicrobial therapy 30 3E.5.2.3 Adjunctive measures 31 3F CATHETER-ASSOCIATED UTIs 31 3F .1 Introduction 31 3F .2 Methods 31 3F .3 Classification systems 31 3F .4 Diagnostic evaluation 32 3F .5 Disease management 32 3F .6 Summary of recommendations 32 3G UTIs IN CHILDREN 33 3G.1 Introduction 33 3G.2 Epidemiology, aetiology and pathophysiology 34 3G.3 Classification systems 34 3G.4 Diagnostic evaluation 35 3G.4.1 Physical (...) ). These Guidelines cover male and female UTIs, male genital infections and special fields such as UTIs in paediatric urology and risk factors, e.g. immunosuppression, renal insufficiency and diabetes mellitus. Much attention is given to peri-operative antibacterial prophylaxis (ABP), aiming to reduce the overuse of antimicrobial agents in conjunction with surgery. High quality clinical research using strict internationally recognised definitions and classifications, as presented in these Guidelines

2015 European Association of Urology

182. Urological Trauma

Trauma prepared these guidelines in order to assist medical professionals in the management of urological trauma in adults. Paediatric trauma is addressed in the EAU Paediatric Urology Guidelines. 1.2 Panel composition The EAU Urological Trauma Guidelines Panel consists of an international group of clinicians with particular expertise in this area. 1.2.1 Potential conflict of interest The expert panel have submitted potential conflict of interest statements which can be viewed on the EAU website. 1.3 (...) violence, child and sexual abuse, and MVAs [8]. 3.1.1 Genito-Urinary Trauma Genito-urinary trauma is seen in both sexes and in all age groups, but is more common in males. The kidney is the most commonly injured organ in the genito-urinary system and renal trauma is seen in up to 5% of all trauma cases [9, 10], and in 10% of all abdominal trauma cases [11]. In MVAs, renal trauma is seen after direct impact into the seatbelt or steering wheel (frontal crashes) or from body panel intrusion in side-impact

2015 European Association of Urology

185. Intravesical instillation with mitomycin C or bacillus Calmette-Guérin in non-muscle invasive bladder cancer

, therapeutic irrigation, intravesical drug administration, and administration, intravesical. Non-English-language studies, animal or in vitro studies, conference proceedings, and paediatric studies were excluded. The search was based on PICO questions formulated by the Working Group. (Appendix 14.11) 2.2 Limitation of the search Limitations: • English language • Adults The search results were not limited to randomised controlled trials (RCTs), controlled clinical 9 Intravesical instillation – March 2015 (...) is more common, resulting in chemical cystitis, allergic rash, and palmar or genital desquamation from contact dermatitis. [57] 9.2.1 Side effects Local side effects: chemical cystitis Administration of cytotoxic chemotherapy into the bladder can induce an array of irritative voiding symptoms. Most of the adverse effects occur during the first 6 months of therapy. [78] These side effects may be treated symptomatically: • dysuria • frequency • urgency • suprapubic discomfort • gross haematuria • pelvic

2015 European Association of Urology Nurses

186. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia

noted no cases of urinary incontinence or sexual dysfunction. Minor complications included transient dysuria (70%) and urgency (40%), and slight haematuria (30%). Two patients (10%) needed post-operative catheterisation. The authors stated that longer follow-up times and larger patient numbers were needed before conclusions could be made on the safety and efficacy of the technology. An average of 3.8 UroLift implants was used per patient. 3.11 Chin et al. (2012) and Woo et al. (2012) both reported (...) reserved. Subject to Notice of rights ( conditions#notice-of-rights). Page 11 of 35some patients continued to show a 34% symptomatic improvement. Similar improvements were shown in BPHII and quality of life. Results were statistically significant for all of these outcomes at all time intervals. No decrease in sexual function was observed, and the MSHQ-EjD showed significant improvements at some intervals. Adverse events were minor, such as dysuria and haematuria

2015 National Institute for Health and Clinical Excellence - Medical technologies

187. Accidental ketosis-induced polyuria in a toddler: a case report. Full Text available with Trip Pro

Accidental ketosis-induced polyuria in a toddler: a case report. In the pediatric population, parental concern of recent onset frequent or large volume urination in young children is common.A 2-year-old male with no significant past medical history and unremarkable family history was brought to his pediatrician by his mother who reports that the child had been "soaking through his diapers" for the previous two to 3 days. Mother states that patient has not had an appreciable change in the number (...) of wet diapers per day, just the perceived weight/volume of each diaper. The patient's mother denied any recent illness, apparent abdominal pain, dysuria, or recent changes in his bowel movements. She similarly denied polydipsia, polyphagia, or gross hematuria in the patient. Patient's diet consists of eating a low carbohydrate with mostly high protein and fat diet that was similar to the paleo-type diet consumed by her and her husband. Meals over the recent days were even lower in carbohydrates than

2019 BMC Pediatrics

188. A Randomized Control Trial Comparing Outcome after Stented and Nonstented Anderson-Hynes Dismembered Pyeloplasty. Full Text available with Trip Pro

A Randomized Control Trial Comparing Outcome after Stented and Nonstented Anderson-Hynes Dismembered Pyeloplasty. The aim of the study was to compare the efficacy and postoperative complications of stented and nonstented open pediatric dismembered pyeloplasty for ureteropelvic junction (UPJ) obstruction.A balanced, parallel group, prospective randomized controlled trial comparing stented and nonstented Anderson-Hynes Dismembered Pyeloplasty.It included 42 children who required Anderson-Hynes (...) dismembered pyeloplasty for UPJ obstruction (UPJO). Patients were randomized into stented (double "J" [DJ] stent) and nonstented pyeloplasty groups. The intraoperative and postoperative course was compared. Both groups were analyzed for problems such as dysuria, frequency, pain, hematuria and urinary tract infection, and postoperative renal status.Mann-Whitney U-test, Fisher's exact test, Student's t-tests, and Chi-squared test were used.Surgical duration was significantly shorter for the nonstented group

2019 Journal of Indian Association of Pediatric Surgeons Controlled trial quality: uncertain

190. Vaginal Cancer Treatment (PDQ®): Health Professional Version

Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. Version History NBK65801.8 November 15, 2019 (Displayed Version) February 7, 2019 February 6, 2018 January 30, 2018 February 9, 2017 January 26, 2017 February 9, 2016 July 15, 2015 In this Page Related publications Related information Links to PubMed Similar articles in PubMed [PDQ Cancer Information Summari...] Review Childhood Cervical and Vaginal Cancer Treatment (PDQ®): Health Professional Version PDQ Pediatric Treatment (...) third of the vagina. In women who had not previously undergone hysterectomy, upper vaginal lesions were found in 17 of 50 women (34%). Clinical Features Although early vaginal cancer may not cause noticeable signs or symptoms, possible signs and symptoms of vaginal cancer include the following: Metrorrhagia. Dyspareunia. Pelvic pain. Vaginal mass. Dysuria. Constipation. Diagnostic Evaluation The following procedures may be used to diagnose vaginal cancer: History and physical exam. Pelvic exam

2017 PDQ - NCI's Comprehensive Cancer Database

191. Perjeta - pertuzumab

, complete quality data, non- clinical and clinical data based on applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies). Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/345/2010 on the granting of a class waiver. Information relating to orphan market exclusivity Similarity Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3

2013 European Medicines Agency - EPARs

192. Dalbavancin hydrochloride (HCl) (Dalvance)

currently breastfeeding an infant. 3. Patients with sustained shock, defined as systolic blood pressure 8 µg/mL). 7. Patients with evidence of meningitis, necrotizing fasciitis, gas gangrene, gangrene, septic arthritis, osteomyelitis; endovascular infection, such as clinical and/or echocardiographic evidence of endocarditis or septic thrombophlebitis. 8. Infections caused exclusively by Gram-negative bacteria (without Gram-positive bacteria present) and infections caused by fungi, whether alone

2013 FDA - Drug Approval Package

193. Caprelsa - vandetanib

data based on applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain tests or studies. Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/94/2008 on the agreement of a paediatric investigation plan (PIP). At the time of submission of the application, the PIP EMEA-000052-PIP01-07 was not yet completed as some measures were deferred. Information relating to orphan market (...) monotherapy. However, a total of 4 cases of RPLS have occurred in the vandetanib programme. One case occurred in Study 32 in a patient who received vandetanib 100 mg daily in combination with chemotherapy for NSCLC. Two cases occurred in paediatric patients with primary brain tumours receiving vandetanib with concomitant radiotherapy in investigator-sponsored (Study IRUSZACT0051). One case occurred in Study IRUSZACT0070 in a patient receiving vandetanib in combination with gemcitabine + oxaliplatin

2012 European Medicines Agency - EPARs

194. Constella - linaclotide

recommended use of linaclotide to adults, especially since GC-C receptor is overexpressed in young children. Specific studies will need to be conducted before a conclusion on safe and effective use in the paediatric population can be made. Linaclotide is expected to offer a useful treatment option for patients with moderate or severe IBS with constipation, once organic diseases have been ruled out and a diagnosis of IBS-C has been established. The Committee’s conclusion that the medicine’s benefits (...) to be more common in the elderly, leading to its recommendation that prescribers should afford special attention to older patients and assess the medicine’s benefits and risks carefully before and during treatment in this age group. To further elucidate the safety profile of the medicine in this population, the Agency has requested a post-authorisation safety study that specifically includes elderly patients. Regarding children and adolescents, the absence of data led the Agency to restrict its

2012 European Medicines Agency - EPARs

195. Aclidinium bromide (Tudorza Pressair)

for Adverse Events 133 7.5.3 Drug-Demographic Interactions 133 7.5.4 Drug-Disease Interactions 135 7.5.5 Drug-Drug Interactions 137 7.6 Additional Safety Evaluations 138 7.6.1 Human Carcinogenicity 138 7.6.2 Human Reproduction and Pregnancy Data 140 7.6.3 Pediatrics and Assessment of Effects on Growth 140 Reference ID: 3136667Clinical Review Jennifer Rodriguez Pippins, MD, MPH NDA 202-450 Turdoza Pressair (aclidinium bromide) 4 7.6.4 Overdose, Drug Abuse Potential, Withdrawal and Rebound 141 7.7

2012 FDA - Drug Approval Package

196. Mirabegron (Myrbetriq)

315 7.4.3 Vital Signs 332 7.4.4 Electrocardiograms (ECGs) 340 7.4.5 Special Safety Studies/Clinical Trials 344 7.4.6 Immunogenicity 344 7.5 Other Safety Explorations 347 7.5.1 Dose Dependency for Adverse Events 347 7.5.2 Time Dependency for Adverse Events 349 7.5.3 Drug-Demographic Interactions 349 7.5.5 Drug-Drug Interactions 354 7.6 Additional Safety Evaluations 356 7.6.1 Human Carcinogenicity 356 7.6.2 Human Reproduction and Pregnancy Data 356 7.6.3 Pediatrics and Assessment of Effects (...) is required in patients with mild to moderate renal impairment according to the Sponsor. Volunteers with hepatic impairment were compared pharmacokinetically to healthy control volunteers who were matched for sex, age and body mass index (BMI). Following single dose administration of 100 mg mirabegron in volunteers with mild hepatic impairment (Child-Pugh Class A), mean mirabegron C max and AUC inf were increased by 9% and 19% relative to volunteers with normal hepatic function. In volunteers

2012 FDA - Drug Approval Package

197. ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease

urethrogram. (Stricture length is defined as the distance between the most distal edge of the stricture to the most proximal edge of the stricture). Two or more prior dilation treatments of the same stricture, including DVIU (Direct Vision Internal Urethrotomy), but no prior urethroplasty. Significant symptoms of stricture such as frequency of urination, dysuria, urgency, hematuria, slow flow, feeling of incomplete emptying, recurrent urinary tract infections (UTI's). International Prostrate Symptoms (...) the study quality of life questionnaires Unwilling to use protected sex for thirty (30) days' post treatment Unwilling to abstain or use protected sex for ninety (90) days post treatment if sexual partner is of child bearing potential. Inability to provide Informed Consent Form (ICF) and/or comply with all the required follow-up requirements Participation in other pre-market studies or treatment with an investigational drug or device. Long term follow up or post market study of an approved device

2018 Clinical Trials

198. Enuresis Alarm

in children, and use of bedwetting alarms has shown the best long-term success. However, use of alarms is very time-intensive, often taking months before yielding results. Researchers in the division of pediatric urology are initiating a randomized controlled study comparing a standard bedwetting alarm with a newly developed technology, with the hope that the new alarm will result in better, more rapid, and easier treatment for bedwetting. Children between the ages of 5 to 15 years old who have issues (...) for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: children ages 5-15 years Diagnosis of Primary Monosymptomatic Nocturnal Enuresis >2 wet nights per week Score of 7 or below on questions 1-6 and 9-13 on Vancouver Dysfunctional Elimination Questionnaire Patients/parents compliance in recording data > 50% of nights Exclusion Criteria: Known comorbid conditions: daytime incontinence, anatomic abnormalities (hydronephrosis, VUR), recurrent urinary tract infection, dysuria

2018 Clinical Trials

199. Laser Therapy for Treatment of Urogenital Symptoms in Women

Bladder, Overactive Urinary Tract Infections Stress Urinary Incontinence Device: fCO2 Laser Therapy Group Detailed Description: Fractional carbon dioxide (fCO2) laser treatment of the vaginal tissue has been proposed as a treatment for various genitourinary symptoms, including vaginal itching, burning, dryness, dyspareunia (difficult or painful sexual intercourse), dysuria (painful or difficult urination), nocturia (waking at night to urinate), incontinence (the involuntary loss of urine), urine (...) sexual functioning. Scores range from 2-36. A score of 26.55 has been clinically selected as the cut-off for sexual dysfunction. Scores below this value indicate sexual dysfunction. Change in frequency of UTI occurrences, as measured by a positive urine culture test. [ Time Frame: 6 months and 36 months post-initial treatment ] A clean catch urine specimen will be collected at each visit. A positive urine dipstick test will have the presence of leukocytes and nitrites accompanied by symptoms (dysuria

2018 Clinical Trials

200. Can lichen sclerosus be diagnosed by preputial appearance or symptoms? Full Text available with Trip Pro

Can lichen sclerosus be diagnosed by preputial appearance or symptoms? Lichen sclerosus (LS), or balanitis xerotica obliterans, is a chronic, inflammatory disease accompanied by cicatrizing skin conditions resulting in pathologic phimosis. LS can be detected clinically by the whitish appearance of the glans or the foreskin, thickened, nonretractable foreskin, dysuria, and spraying. However, diagnosis is confirmed histopathologically.The aim of this study was to investigate whether LS can (...) be diagnosed on the basis of clinical manifestation and symptoms.A retrospective analysis was performed, which included boys referred to our institutions for phimosis evaluation between May 2001 and December 2016. Pediatric urologists clinically diagnosed LS preoperatively. Boys with voiding problems, recurrent balanoposthitis, or who were unresponsive to topical steroid treatment underwent surgical treatment. Patients who underwent religious circumcisions were not included.Three-hundred twenty boys

2018 Research and reports in urology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>